• Allarity Therapeutics is now poised to run its DRP® testing in-house in a CLIA-certified laboratory environment



     
  • The FDA requires that biomarker testing to select patients for registration trials must be performed in a CLIA-certified laboratory environment



     
  • CLIA certification for the Allarity Therapeutics Medical Laboratory is a critical strategic initiative to streamline the development of Allarity’s lead agent, stenoparib



    • Positions Allarity Therapeutics Medical Laboratory as a preferred CLIA-certified partner for European companies pursuing U.S. clinical trials or commercialization